Status:

UNKNOWN

Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

Lead Sponsor:

American Scitech International

Collaborating Sponsors:

Eli Lilly and Company

Bristol-Myers Squibb

Conditions:

Hodgkin's Disease

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine and Dacarbazine. R-mabH...

Detailed Description

The primary objective is to compare the efficacy of R-mabHD with a combination therapy of Adriamycin, Bleomycin,Vinblastine and Dacarbazine (ABVD) in bringing about remission of Hodgkin's lymphoma and...

Eligibility Criteria

Inclusion

  • Must sign an informed consent form
  • Must have histologically proven diagnosis of Hodgkin's lymphoma
  • Both genders and age between 18 and 65
  • Must have adequate bone marrow reserve (ANC.1500/mm3, Platelet\>50,000/mm3)
  • Must have bidimensionally measureable disease
  • LVEF \>50% by echocardiogram
  • Serum creatinine upto one fold
  • Serum bilirubin upto one fold
  • Hepatitis B surface antigen negative
  • Hodgkin's Disease patients who relapse after radiation therapy alone or surgical treatment alone or both,or previously untreated patients with stage II bulky, III and IV.

Exclusion

  • HIV positive
  • Pregnant women and women of child bearing age who are not practising adequate contraception
  • Severe pulmonary disease including COPD and asthma
  • Evidence of other malignancy except superficial nonmelanoma skin carcinoma or carcinoma in situ of the cervix
  • Nursing mothers
  • Uncontrolled active infection
  • concurrent prednisone or other systemic steroid therapy
  • Less than 4 weeks since prior radiotherapy
  • Less than 30 days since prior investigational therapy.

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2014

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00797472

Start Date

July 1 2011

End Date

April 1 2014

Last Update

July 20 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Raritan Bay Medical Center

Englishtown, New Jersey, United States, 07726